Selection of cyclic-peptide inhibitors targeting Aurora kinase A

Problems and solutions

Carolyn D. Shomin, Elizabeth Restituyo, Kurt J. Cox, Indraneel Ghosh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The critical role of Aurora kinase in cell cycle progression and its deregulation in cancer has garnered significant interest. As such, numerous Aurora targeted inhibitors have been developed to date, almost all of which target the ATP cleft at the active site. These current inhibitors display polypharmacology; that is, they target multiple kinases, and some are being actively pursued as therapeutics. Currently, there are no general approaches for targeting Aurora at sites remote from the active site, which in the long term may provide new insights regarding the inhibition of Aurora as well as other protein kinases, and provide pharmacological tools for dissecting Aurora kinase biology. Toward this long term goal, we have recently developed a bivalent selection strategy that allows for the identification of cyclic peptides that target the surface of PKA, while the active site is blocked by an ATP-competitive compound. Herein, we extend this approach to Aurora kinase (Aurora A), which required significant optimization of selection conditions to eliminate background peptides that target the streptavidin matrix upon which the kinases are immobilized. Using our optimized selection conditions, we have successfully selected several cyclic peptide ligands against Aurora A. Two of these inhibitors demonstrated IC 50 values of 10 μM and were further interrogated. The CTRPWWLC peptide was shown to display a noncompetitive mode of inhibition suggesting that alternate sites on Aurora beyond the ATP and peptide substrate binding site may be potentially targeted.

Original languageEnglish (US)
Pages (from-to)6743-6749
Number of pages7
JournalBioorganic and Medicinal Chemistry
Volume19
Issue number22
DOIs
StatePublished - Nov 15 2011

Fingerprint

Aurora Kinases
Aurora Kinase A
Cyclic Peptides
Catalytic Domain
Adenosine Triphosphate
Peptides
Polypharmacology
Phosphotransferases
Deregulation
Streptavidin
Protein Kinases
Cell Cycle
Binding Sites
Cells
Pharmacology
Ligands
Substrates
Neoplasms
Therapeutics

Keywords

  • Cyclic peptide
  • Kinome
  • Peptide
  • Phage display
  • Protein kinase
  • Selection
  • Streptavidin

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Selection of cyclic-peptide inhibitors targeting Aurora kinase A : Problems and solutions. / Shomin, Carolyn D.; Restituyo, Elizabeth; Cox, Kurt J.; Ghosh, Indraneel.

In: Bioorganic and Medicinal Chemistry, Vol. 19, No. 22, 15.11.2011, p. 6743-6749.

Research output: Contribution to journalArticle

Shomin, Carolyn D. ; Restituyo, Elizabeth ; Cox, Kurt J. ; Ghosh, Indraneel. / Selection of cyclic-peptide inhibitors targeting Aurora kinase A : Problems and solutions. In: Bioorganic and Medicinal Chemistry. 2011 ; Vol. 19, No. 22. pp. 6743-6749.
@article{ba72951953ad471788ffb654d986d6ad,
title = "Selection of cyclic-peptide inhibitors targeting Aurora kinase A: Problems and solutions",
abstract = "The critical role of Aurora kinase in cell cycle progression and its deregulation in cancer has garnered significant interest. As such, numerous Aurora targeted inhibitors have been developed to date, almost all of which target the ATP cleft at the active site. These current inhibitors display polypharmacology; that is, they target multiple kinases, and some are being actively pursued as therapeutics. Currently, there are no general approaches for targeting Aurora at sites remote from the active site, which in the long term may provide new insights regarding the inhibition of Aurora as well as other protein kinases, and provide pharmacological tools for dissecting Aurora kinase biology. Toward this long term goal, we have recently developed a bivalent selection strategy that allows for the identification of cyclic peptides that target the surface of PKA, while the active site is blocked by an ATP-competitive compound. Herein, we extend this approach to Aurora kinase (Aurora A), which required significant optimization of selection conditions to eliminate background peptides that target the streptavidin matrix upon which the kinases are immobilized. Using our optimized selection conditions, we have successfully selected several cyclic peptide ligands against Aurora A. Two of these inhibitors demonstrated IC 50 values of 10 μM and were further interrogated. The CTRPWWLC peptide was shown to display a noncompetitive mode of inhibition suggesting that alternate sites on Aurora beyond the ATP and peptide substrate binding site may be potentially targeted.",
keywords = "Cyclic peptide, Kinome, Peptide, Phage display, Protein kinase, Selection, Streptavidin",
author = "Shomin, {Carolyn D.} and Elizabeth Restituyo and Cox, {Kurt J.} and Indraneel Ghosh",
year = "2011",
month = "11",
day = "15",
doi = "10.1016/j.bmc.2011.09.049",
language = "English (US)",
volume = "19",
pages = "6743--6749",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "22",

}

TY - JOUR

T1 - Selection of cyclic-peptide inhibitors targeting Aurora kinase A

T2 - Problems and solutions

AU - Shomin, Carolyn D.

AU - Restituyo, Elizabeth

AU - Cox, Kurt J.

AU - Ghosh, Indraneel

PY - 2011/11/15

Y1 - 2011/11/15

N2 - The critical role of Aurora kinase in cell cycle progression and its deregulation in cancer has garnered significant interest. As such, numerous Aurora targeted inhibitors have been developed to date, almost all of which target the ATP cleft at the active site. These current inhibitors display polypharmacology; that is, they target multiple kinases, and some are being actively pursued as therapeutics. Currently, there are no general approaches for targeting Aurora at sites remote from the active site, which in the long term may provide new insights regarding the inhibition of Aurora as well as other protein kinases, and provide pharmacological tools for dissecting Aurora kinase biology. Toward this long term goal, we have recently developed a bivalent selection strategy that allows for the identification of cyclic peptides that target the surface of PKA, while the active site is blocked by an ATP-competitive compound. Herein, we extend this approach to Aurora kinase (Aurora A), which required significant optimization of selection conditions to eliminate background peptides that target the streptavidin matrix upon which the kinases are immobilized. Using our optimized selection conditions, we have successfully selected several cyclic peptide ligands against Aurora A. Two of these inhibitors demonstrated IC 50 values of 10 μM and were further interrogated. The CTRPWWLC peptide was shown to display a noncompetitive mode of inhibition suggesting that alternate sites on Aurora beyond the ATP and peptide substrate binding site may be potentially targeted.

AB - The critical role of Aurora kinase in cell cycle progression and its deregulation in cancer has garnered significant interest. As such, numerous Aurora targeted inhibitors have been developed to date, almost all of which target the ATP cleft at the active site. These current inhibitors display polypharmacology; that is, they target multiple kinases, and some are being actively pursued as therapeutics. Currently, there are no general approaches for targeting Aurora at sites remote from the active site, which in the long term may provide new insights regarding the inhibition of Aurora as well as other protein kinases, and provide pharmacological tools for dissecting Aurora kinase biology. Toward this long term goal, we have recently developed a bivalent selection strategy that allows for the identification of cyclic peptides that target the surface of PKA, while the active site is blocked by an ATP-competitive compound. Herein, we extend this approach to Aurora kinase (Aurora A), which required significant optimization of selection conditions to eliminate background peptides that target the streptavidin matrix upon which the kinases are immobilized. Using our optimized selection conditions, we have successfully selected several cyclic peptide ligands against Aurora A. Two of these inhibitors demonstrated IC 50 values of 10 μM and were further interrogated. The CTRPWWLC peptide was shown to display a noncompetitive mode of inhibition suggesting that alternate sites on Aurora beyond the ATP and peptide substrate binding site may be potentially targeted.

KW - Cyclic peptide

KW - Kinome

KW - Peptide

KW - Phage display

KW - Protein kinase

KW - Selection

KW - Streptavidin

UR - http://www.scopus.com/inward/record.url?scp=80055003734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055003734&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2011.09.049

DO - 10.1016/j.bmc.2011.09.049

M3 - Article

VL - 19

SP - 6743

EP - 6749

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 22

ER -